Cellectis (CLLS)

• Market cap: $327M
• 1 day: -0.61%
• 5 days: -8.17%
• 1 month: -7.65%
• 3 months: 28.85%
• 6 months: 103.75%
• Year to date: 80.11%
• 1 year: 83.15%
• 5 years: -82.02%
• 10 years: -92.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222